top of page
3D Scans

NeuroTheranostics

NeuroTheranostics, Inc. (NTI) is a privately held preclinical development-stage neuroscience company that was formed in February 2015 to develop novel therapies and diagnostics for traumatic brain injury (TBI) and TBI-associated neurodegenerative disorders. NTI will make a significant impact on the TBI therapeutics and chronic TBI diagnostics market with an intranasal or intravenous-infusion therapy to be administered starting from the acute to subacute stages of TBI, i.e., within hours to days following the initial traumatic event. The R&D outfit of the company is located in a business and technology park (TechTown) in Detroit, Michigan. Our management and scientific/clinical advisory teams bring together the complementary expertise of business and finance experts with decades of experience in multiple technology startups, large scale turnarounds, and large financial exits and post-merger restructurings, neuroscientists with TBI drug and diagnostic development expertise, neurosurgeons, and emergency and critical care doctors with interest and clinical experience in TBI drug development and treatment.

bottom of page